Sharps Compliance Corporation
SHARPS COMPLIANCE CORP (Form: 10-Q, Received: 11/04/2015 13:33:35)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015
OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to                  .

Commission File Number:  001-34269
 


SHARPS COMPLIANCE CORP.
(Exact name of registrant as specified in its charter)

Delaware
74-2657168
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)

9220 Kirby Drive, Suite 500, Houston, Texas
77054
(Address of principal executive offices)
(Zip Code)
 
(713) 432-0300
(Registrant’s telephone number, including area code)

Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes No 

Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act of 1934.

Large Accelerated Filer
Accelerated Filer
Non-accelerated Filer
 (Do not check if a smaller reporting company)
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes No

As of November 2, 2015, there were 15,487,716 outstanding shares of the Registrant's common stock, par value $0.01 per share.
 


SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
 
     
PART I
FINANCIAL INFORMATION
PAGE
     
Item 1.
Financial Statements
 
     
 
3
     
 
4
     
 
5
     
 
6
     
 
7
     
Item 2.
12
     
Item 3.
18
     
Item 4.
18
     
Part II
OTHER INFORMATION
 
     
Item 1.
19
     
Item 1A.
19
     
Item 2.
19
     
Item 6.
19
     
 
20
 
2

PART I
FINANCIAL INFORMATION
ITEM 1.
FINANCIAL STATEMENTS

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and par value)

   
September 30,
   
June 30,
 
   
2015
   
2015
 
         
ASSETS
       
CURRENT ASSETS
       
Cash and cash equivalents
 
$
15,956
   
$
15,157
 
Accounts receivable, net of allowance for doubtful accounts of $39 and $34, respectively
   
4,892
     
6,647
 
Inventory
   
3,419
     
2,738
 
Prepaid and other current assets
   
553
     
733
 
TOTAL CURRENT ASSETS
   
24,820
     
25,275
 
                 
PROPERTY, PLANT AND EQUIPMENT, net
   
4,175
     
3,810
 
                 
GOODWILL
   
413
     
-
 
                 
INTANGIBLE ASSETS, net of accumulated amortization of $406 and  $385, respectively
   
912
     
666
 
TOTAL ASSETS
 
$
30,320
   
$
29,751
 
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
CURRENT LIABILITIES
               
Accounts payable
 
$
1,439
   
$
1,770
 
Accrued liabilities
   
2,034
     
1,917
 
Deferred revenue
   
1,910
     
1,877
 
TOTAL CURRENT LIABILITIES
   
5,383
     
5,564
 
                 
LONG-TERM DEFERRED REVENUE, net of current portion
   
501
     
483
 
                 
OTHER LONG-TERM LIABILITIES
   
221
     
118
 
                 
TOTAL LIABILITIES
   
6,105
     
6,165
 
                 
COMMITMENTS AND CONTINGENCIES
               
                 
STOCKHOLDERS' EQUITY
               
Common stock, $0.01 par value per share; 20,000,000 shares authorized; 15,676,466 and 15,575,041 shares issued, respectively and 15,485,216 and 15,383,791 shares outstanding, respectively
   
157
     
156
 
Treasury stock, at cost, 191,250 shares repurchased
   
(809
)
   
(809
)
Additional paid-in capital
   
24,752
     
24,344
 
Retained earnings (accumulated deficit)
   
115
     
(105
)
TOTAL STOCKHOLDERS' EQUITY
   
24,215
     
23,586
 
                 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
 
$
30,320
   
$
29,751
 

The accompanying notes are an integral part of these condensed consolidated financial statements.
 
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per-share data)

    
Three-Months
Ended September 30,
 
   
2015
   
2014
 
         
REVENUES
 
$
7,869
   
$
7,047
 
Cost of revenues
   
4,990
     
4,713
 
GROSS PROFIT
   
2,879
     
2,334
 
                 
Selling, general and administrative
   
2,596
     
2,323
 
Depreciation and amortization
   
52
     
85
 
                 
OPERATING INCOME (LOSS)
   
231
     
(74
)
                 
INTEREST INCOME
   
9
     
8
 
TOTAL INTEREST INCOME
   
9
     
8
 
                 
INCOME (LOSS) BEFORE INCOME TAXES
   
240
     
(66
)
                 
INCOME TAX EXPENSE - Current
   
20
     
8
 
                 
TOTAL INCOME TAX EXPENSE
   
20
     
8
 
                 
NET INCOME (LOSS)
 
$
220
   
$
(74
)
                 
NET INCOME (LOSS) PER COMMON SHARE
               
Basic
 
$
0.01
   
$
(0.00
)
                 
Diluted
 
$
0.01
   
$
(0.00
)
                 
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE:
               
                 
Basic
   
15,419
     
15,288
 
Diluted
   
15,926
     
15,288
 

The accompanying notes are an integral part of these condensed consolidated financial statements.
 
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands, except share data)

                   
Additional
   
Retained Earnings
   
Total
 
   
Common Stock
   
Treasury Stock
   
Paid-in
   
(Accumulated
   
Stockholders'
 
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Deficit)
   
Equity
 
                             
Balances, June 30, 2014
   
15,460,940
   
$
155
     
(161,801
)
 
$
(681
)
 
$
23,695
   
$
(1,265
)
 
$
21,904
 
Exercise of stock options
   
61,109
     
-
     
-
     
-
     
139
     
-
     
139
 
Stock-based compensation
   
-
     
-
     
-
     
-
     
511
     
-
     
511
 
Issuance of restricted stock
   
52,992
     
1
     
-
     
-
     
(1
)
   
-
     
-
 
Shares repurchased
   
-
     
-
     
(29,449
)
   
(128
)
   
-
     
-
     
(128
)
Net income
   
-
     
-
     
-
     
-
     
-
     
1,160
     
1,160
 
                                                         
Balances, June 30, 2015
   
15,575,041
     
156
     
(191,250
)
   
(809
)
   
24,344
     
(105
)
   
23,586
 
Exercise of stock options
   
101,425
     
1
     
-
     
-
     
267
     
-
     
268
 
Stock-based compensation
   
-
     
-
     
-
     
-
     
141
     
-
     
141
 
Net income
   
-
     
-
     
-
     
-
     
-
     
220
     
220
 
                                                         
Balances, September 30, 2015
   
15,676,466
   
$
157
     
(191,250
)
 
$
(809
)
 
$
24,752
   
$
115
   
$
24,215
 

The accompanying notes are an integral part of these condensed consolidated financial statements.
 
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)

   
Three-Months Ended
September 30,
 
   
2015
   
2014
 
     
CASH FLOWS FROM OPERATING ACTIVITIES
       
Net income (loss)
 
$
220
   
$
(74
)
Adjustments to reconcile net income (loss) to net cash provided by  operating activities:
               
Depreciation and amortization
   
188
     
242
 
Stock-based compensation expense
   
141
     
116
 
Changes in operating assets and liabilities, net of effects of business acqusition:
               
Restricted cash
   
-
     
111
 
Accounts receivable
   
1,806
     
255
 
Legal settlement receivable
   
-
     
1,538
 
Inventory
   
(681
)
   
(113
)
Prepaid and other current assets
   
180
     
(144
)
Accounts payable and accrued liabilities
   
(282
)
   
331
 
Deferred revenue
   
51
     
334
 
NET CASH PROVIDED BY OPERATING ACTIVITIES
   
1,623
     
2,596
 
                 
CASH FLOWS FROM INVESTING ACTIVITIES
               
Purchase of property, plant and equipment
   
(462
)
   
(46
)
Payments for acquisition, net of cash acquired
   
(630
)
   
-
 
NET CASH USED IN INVESTING ACTIVITIES
   
(1,092
)
   
(46
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Proceeds from exercise of stock options
   
268
     
-
 
Shares repurchased
   
-
     
(128
)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
   
268
     
(128
)
                 
NET INCREASE IN CASH AND CASH EQUIVALENTS
   
799
     
2,422
 
                 
CASH AND CASH EQUIVALENTS, beginning of period
   
15,157
     
13,717
 
                 
CASH AND CASH EQUIVALENTS, end of period
 
$
15,956
   
$
16,139
 
                 
SUPPLEMENTAL CASH FLOW DISCLOSURES:
               
Income taxes paid
 
$
85
   
$
10
 
                 
Escrow related to acquisition
 
$
70
   
$
-
 

The accompanying notes are an integral part of these condensed consolidated financial statements.
 
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.), Sharps Safety, Inc. and Alpha Bio/Med Services LLC (collectively, “Sharps” or the “Company”).  All significant intercompany accounts and transactions have been eliminated upon consolidation.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of September 30, 2015, the results of its operations for the three months ended September 30, 2015 and 2014, cash flows for the three months ended September 30, 2015 and 2014 and stockholders’ equity for the three months ended September 30, 2015 and the year ended June 30, 2015. The results of operations for the three months ended September 30, 2015 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2016.  These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2015.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition The Company recognizes revenue from product sales and services when goods are shipped or delivered, services provided, and title and risk of loss pass to the customer except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.  Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse.  During the three months ended September 30, 2015 and 2014, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.6 million and $0.8 million respectively.  As of September 30, 2015 and June 30, 2015, $1.9 and $1.6 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program.

Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ and various other solutions like the TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service.

In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.  The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.  The selling price for the transportation revenue and the treatment revenue utilizes third party evidence.  The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.  Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities.  The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities.  Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.  Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.  The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.  Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned.  Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.
 
Income Taxes :  Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets.  Under generally accepted accounting principles, the valuation allowance has been recorded to reduce our deferred tax assets to an amount that is more likely than not to be realized and is based on the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.

Accounts Receivable :  Accounts receivable consist primarily of amounts due to the Company from our normal business activities.   Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer.  The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts.  Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.

Stock-Based Compensation : Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).

NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, guidance for revenue recognition was issued which supersedes the revenue recognition requirements currently followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. In July 2015, the FASB decided to defer the original effective date by one year to be effective for annual reporting periods beginning after December 15, 2017 instead of December 15, 2016 for public entities (effective July 1, 2018 for the Company).  The Company is still evaluating the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures and has not yet determined the method by which it will adopt the standard.

In July 2015, guidance for inventory measurement was issued, which supersedes the policy currently followed by the Company.  The new guidance requires the Company to measure inventory at the lower of cost or net realizable value.  The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2016 (effective July 1, 2017 for the Company) including interim periods within the reporting period.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In September 2015, guidance for business combinations was issued, which simplifies the accounting for measurement-period adjustments.  The new guidance eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination and requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified.  The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2015 (effective July 1, 2016 for the Company) including interim periods within the reporting period.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

NOTE 5 - INCOME TAXES

The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under generally accepted accounting principles, the valuation allowance has been recorded to reduce the Company’s net deferred tax asset to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.  The Company’s net deferred tax assets have been fully reserved by a tax valuation allowance.
 
The Company’s effective tax rate for the three months ended September 30, 2015 and 2014 was 8.3% and (12.1%), respectively, reflecting estimated state income taxes. The Company’s tax expense associated with taxable income during the three months ended September 30, 2015 was offset by the utilization of net operating loss carryforwards. The Company’s tax benefit associated with taxable losses during the three months ended September 30, 2014 was offset by a deferred tax valuation allowance.

NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

On April 9, 2015, the Company entered into a credit agreement with a commercial bank (“Credit Agreement”). The Credit Agreement, which replaces, in its entirety, the Company’s prior credit agreement, which was executed effective January 28, 2014 with the same commercial bank, provides for a two-year, $9.0 million line of credit facility, the proceeds of which may be utilized as follows: (i) $4.0 million for working capital, letters of credit (up to $500,000) and general corporate purposes and (ii) $5.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by the Company’s accounts receivable and inventory with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus 50% of eligible inventory. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note. Borrowings bear interest at WSJ Prime (for the working capital line) and WSJ Prime plus 0.25% (for the acquisition line), which was approximately 3.25% and 3.50%, respectively, as of September 30, 2015. The Company pays a fee of 0.25% per annum on the unused amount of the line of credit. As of September 30, 2015, the Company had no outstanding borrowings other than $0.3 million in letters of credit, which left $8.7 million of credit available under the Credit Agreement.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $12.5 million, minimum liquidity of $7.0 million and a minimum debt service coverage ratio of not less than 1.15 to 1.00. The Credit Agreement, which expires on April 9, 2017, also contains customary events of default which, if uncured, may terminate the Credit Agreement and require immediate repayment of all indebtedness to the lenders. The Company was in compliance with all the financial covenants under the Credit Agreement as of September 30, 2015.

NOTE 7 – STOCK-BASED COMPENSATION

Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, and subsequent reporting periods, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).  Stock-based compensation costs from performance-based stock option awards are estimated at the date when key terms and conditions of the performance-based stock option award are known (the “service inception date”), and subsequent reporting periods, trued up at the grant date and recognized as expense over the employee’s requisite period (from the service inception date through the end of the vesting period).  During the three months ended September 30, 2015 and 2014, stock-based compensation amounts are as follows (in thousands):

   
Three-Months Ended
 
   
September 30,
 
   
2015
   
2014
 
   
(Unaudited)
 
         
Stock-based compensation expense included in:
       
         
Cost of revenues
 
$
8
   
$
4
 
Selling, general and administrative
   
133
     
112
 
Total
 
$
141
   
$
116
 

NOTE 8 - EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income (loss) by the weighted average number of common shares after considering the additional dilution related to common stock options, restricted stock and performance-based stock option awards. In computing diluted earnings per share, the outstanding common stock options and performance-based stock option awards are considered dilutive using the treasury stock method.

The Company’s restricted stock awards are treated as outstanding for earnings per share calculations since these shares have full voting rights and are entitled to participate in dividends declared on common shares, if any, and undistributed earnings.  As participating securities, the shares of restricted stock are included in the calculation of basic EPS using the two-class method.  For the periods presented, the amount of earnings allocated to the participating securities was not material.
 
The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):
 
   
Three-Months Ended
 
   
September 30,
 
   
2015
   
2014
 
   
(Unaudited)
 
         
Net income (loss), as reported
 
$
220
   
$
(74
)
                 
Weighted average common shares outstanding
   
15,419
     
15,288
 
Effect of dilutive stock options
   
507
     
-
 
Weighted average diluted common shares outstanding
   
15,926
     
15,288
 
                 
Net income (loss) per common share
               
Basic
 
$
0.01
   
$
(0.00
)
Diluted
 
$
0.01
   
$
(0.00
)
                 
Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive
   
216
     
237
 
 
NOTE 9 - EQUITY TRANSACTIONS

During the three months ended September 30, 2015 and 2014, stock options to purchase shares of the Company’s common stock were exercised as follows:

   
Three-Months Ended
September 30,
 
   
2015
   
2014
 
   
(Unaudited)
 
         
Options Exercised
   
101,425
     
-
 
Proceeds (in thousands)
 
$
268
   
$
-
 
Average exercise price per share
 
$
2.64
   
$
-
 

As of September 30, 2015, there was $0.6 million of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.95 years.

On January 7, 2013, the Company announced that its Board of Directors approved a stock repurchase program effective January 3, 2013, authorizing the Company to repurchase in the aggregate up to $3.0 million of its outstanding common stock over a two-year period.  On March 5, 2015, the Board approved a two-year extension on the stock repurchase program through January 1, 2017. During the three months ended September 30, 2015 and 2014, shares were repurchased as follows:

    Three-Months Ended  
   
September 30,
 
   
2015
   
2014
 
   
(Unaudited)
 
         
Shares repurchased
   
-
     
29,449
 
Cash paid for shares repurchased (in thousands)
 
$
-
   
$
128
 
Average price paid per share
 
$
-
   
$
4.35
 
 
Total shares repurchased under the program are 191,250 shares at a cost of $0.8 million.  As of September 30, 2015, approximately $2.2 million remained of the Company’s $3.0 million repurchase program.  Sharps purchased all shares with cash resources.
 
NOTE 10 – INVENTORY

The components of inventory are as follows (in thousands):

   
September 30,
2015
   
June 30,
2015
 
   
(Unaudited)
 
Raw materials
 
$
1,207
   
$
1,345
 
Finished goods
   
2,212
     
1,393
 
Total
 
$
3,419
   
$
2,738
 

NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at September 30, 2015 due to their short-term nature.

NOTE 12 – ACQUISITION

Effective on July 17, 2015, the Company acquired Alpha Bio/Med Services LLC, a route-based pickup service located in Pennsylvania for total cash consideration of $0.7 million of which $0.1 million has been withheld for possible settlement amounts through July 2016. 

The following amounts represent the fair value of the assets acquired and liabilities assumed: 

Accounts receivable
 
$
51
 
Fixed assets
   
70
 
Intangibles
   
267
 
Goodwill
   
413
 
Accounts payable and accrued liabilities
   
(101
)
Total purchase price
 
$
700
 

During the three months ended September 30, 2015, the Company incurred $0.1 million of acquisition related expenses for investment banking, legal and accounting fees which are included within selling, general and administrative expenses on our condensed consolidated statements of operations.  The results of operations of the acquired business have been included in the condensed consolidated statements of operations from the date of acquisition.
 
ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements and information relating to the Company and its subsidiaries that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this report, the words “anticipate”, “believe”, “expect”, “estimate”, “project” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements.  Such statements reflect the current risks, uncertainties and assumptions related to certain factors, including without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein.  Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, expected, estimated or intended.  The Company does not intend to update these forward-looking statements.

GENERAL

Sharps Compliance Corp. is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous. Our solutions facilitate the proper collection, containment, transportation and treatment of numerous types of healthcare-related materials, including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin, or sharps, hazardous waste and unused consumer dispensed medications and over-the-counter drugs.  We serve customers in multiple markets such as home health care, retail clinics and immunizing pharmacies, pharmaceutical manufacturers, professional offices (physicians, dentists and veterinarians), assisted living and long-term care facilities (assisted living, continuing care, long-term acute care, memory care and skilled nursing), government (federal, state and local), consumers, commercial and agriculture, as well as distributors to many of the aforementioned markets.  We assist our customers in determining which of our solution offerings best fit their needs for the collection, containment, return transportation and treatment of medical waste, used healthcare materials, pharmaceutical waste, hazardous waste and unused dispensed medications.  Our differentiated approach provides our customers the flexibility to return and properly treat medical waste, used healthcare materials or unused dispensed medications through a variety of solutions and products transported primarily through the United States Postal Service (“USPS”). For customers with facilities or locations that may generate larger quantities of medical waste, we integrate the route-based pick-up service into our complete offering.  The benefits of this comprehensive offering include single point of contact, consolidated billing, integrated manifest and proof of destruction repository in addition to our cost savings.  Furthermore, we provide comprehensive tracking and reporting tools that enable our customers to meet complex medical, pharmaceutical and hazardous waste disposal and compliance requirements.  We believe the fully-integrated nature of our operations is a key factor leading to our success and continued recurring revenue growth.  We continue to take advantage of the many opportunities in all markets served as we educate the market place and as prospective customers become more aware of alternatives to traditional methods of disposal (i.e., route-based pick-up services).

As a leading full-service provider of comprehensive medical waste management services including medical, pharmaceutical and hazardous, our key markets include pharmaceutical manufacturers, home healthcare providers, assisted living/long-term care, retail pharmacies and clinics and the professional market which is comprised of physicians, dentists and veterinary practices.  The Company’s flagship product, the Sharps ® Recovery System, is a comprehensive solution for the containment, transportation, treatment and tracking of medical waste and used healthcare materials.  In October 2014, the Company launched MedSafe ® , a patent pending solution for the safe collection, transportation and proper disposal of unwanted and expired prescription medications including controlled substances from ultimate users.  MedSafe   has been designed to meet or exceed the new regulations issued by the Drug Enforcement Administration (“DEA”) implementing the Secure and Responsible Drug Disposal Act of 2010 (the “Act”) which became effective October 9, 2014.  In July 2015, the Company augmented its network of medical and hazardous waste service providers with an acquisition of a route-based pickup service in the northeast serving Pennsylvania, Maryland and parts of Ohio. Additionally, the Company has begun to service parts of Texas and Louisiana with route-based pickup service. Our other solutions include TakeAway Medication Recovery System™, ComplianceTRAC SM , Route-Based Pick-Up Service, Universal Waste Shipback Systems, TakeAway Environmental Return System™, SharpsTracer ® , Sharps Secure ® Needle Disposal System™, Complete Needle™ Collection & Disposal System, Pitch-It IV™ Poles, Trip LesSystem ® , Sharps ® Pump and Asset Return System, Sharps ® MWMS™ (a Medical Waste Management System (“MWMS”)) and Biohazard Spill Clean-up Kit and Recovery System™.
 
RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results and financial condition of the Company during the three months ended September 30, 2015 and 2014. The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Operations, dollars in thousands and percentages expressed as a percentage of revenue:

   
Three-Months Ended September 30,
 
   
2015
   
%
   
2014
   
%
 
   
(Unaudited)
 
                 
Revenues
 
$
7,869
     
100.0
%
 
$
7,047
     
100.0
%
                                 
Cost of revenues
   
4,990
     
63.4
%
   
4,713
     
66.9
%
Gross profit
   
2,879
     
36.6
%
   
2,334
     
33.1
%
                                 
SG&A expense
   
2,596
     
33.0
%
   
2,323
     
33.0
%
Depreciation and amortization
   
52
     
0.7
%
   
85
     
1.2
%
                                 
Operating income (loss)
 
$
231
     
2.9
%
 
$
(74
)
   
(1.1
%)
                                 
Interest income
   
9
     
0.1
%
   
8
     
0.1
%
                                 
Income (loss) before income taxes
   
240
     
3.0
%
   
(66
)
   
(0.9
%)
Income tax expense
   
20
     
0.3
%
   
8
     
0.1
%
Net income (loss)
 
$
220
     
2.8
%
 
$
(74
)
   
(1.1
%)
 
THREE MONTHS ENDED SEPTEMBER 30, 2015 AS COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2014

Total revenues for the three months ended September 30, 2015 of $7.9 million increased by $0.8 million, or 12%, over the total revenues for the three months ended September 30, 2014 of $7.0 million. Billings by market are as follows (in thousands):

   
Three-Months Ended September 30,
 
   
(Unaudited)
 
   
2015
   
2014
   
Variance
 
             
BILLINGS BY MARKET:
           
Home Health Care
 
$
1,951
   
$
1,753
   
$
198
 
Retail
   
1,749
     
1,995
     
(246
)
Professional
   
1,711
     
1,451
     
260
 
Pharmaceutical Manufacturer
   
1,239
     
1,385
     
(146
)
Assisted Living
   
526
     
450
     
76
 
Government
   
464
     
134
     
330
 
Environmental
   
79
     
94
     
(15
)
Other
   
262
     
233
     
29
 
Subtotal
   
7,981
     
7,495
     
486
 
GAAP Adjustment *
   
(112
)
   
(448
)
   
336
 
Revenue Reported
 
$
7,869
   
$
7,047
   
$
822
 

*Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue.  Customer billings include all invoiced amounts associated with products shipped during the period reported.  GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction.  The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue.  See Note 3 “Revenue Recognition” in “Notes to Condensed Consolidated Financial Statements”.

This quarter-to-date table contains certain financial information not derived in accordance with GAAP, including customer billings information.  The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported. Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included above.
 
The increase in billings was primarily attributable to increased billings in the Government ($0.3 million), Professional ($0.3 million), Home Health Care ($0.2 million) and Assisted Living ($0.1 million) markets.  The increase was partially offset by decreased billings in the Retail ($0.2 million) and Pharmaceutical Manufacturer ($0.1 million) markets. The increase in Government market billings was primarily related to increased sales of the Company’s MedSafe solutions and TakeAway Medication Recovery System envelopes to multiple Government agencies.  The increase in Professional market billings is a result of continued targeted telemarketing initiatives and promotional activities to educate doctors, dentists, veterinarians and other healthcare professionals about the favorable economics and convenience of the Company’s Sharps Recovery System and our new route-based pickup service. The increase in Home Health Care market billings is due to the timing of distributor purchases. The increase in Assisted Living market billings is a result of increased sales focus as well as our new route-based pickup service.  The decrease in Retail market billings is primarily due to timing of large flu shot orders for the upcoming flu season. The decrease in Pharmaceutical Manufacturer market billings is primarily due to timing of new inventory builds for existing and new customers.

Cost of revenues for the three months ended September 30, 2015 of $5.0 million was 63.4% of revenues.  Cost of revenues for the three months ended September 30, 2014 of $4.7 million was 66.9% of revenues.  The higher gross margin for the three months ended September 30, 2015 of 36.6% (versus 33.1% for the three months ended September 30, 2014) was due to leverage gained from higher revenue.

Selling, general and administrative (“SG&A”) expenses for the three months ended September 30, 2015 and 2014 was $2.6 million and $2.3 million, respectively.  SG&A for the three months ended September 30, 2015 included $0.1 million of acquisition related costs associated with the Company’s acquisition of Alpha Bio/Med in July 2015.  Without these acquisition related costs, SG&A costs increased 8.4% compared to the prior period due to increased sales, marketing and compensation related spending.

The Company generated operating income of $0.2 million for the three months ended September 30, 2015 compared to an operating loss of ($0.1) million for the three months ended September 30, 2014.   The operating income increased mainly due to the increase in revenues and gross profit (discussed above).

The Company generated income before income taxes of $0.2 million for the three months ended September 30, 2015 versus a loss before income taxes of ($0.1) million for the three months ended September 30, 2014. Income before income taxes was positively impacted by improvement in operating income (discussed above).

The Company’s effective tax rate for the three months ended September 30, 2015 and 2014 was 8.3% and (12.1%), respectively, reflecting estimated state income taxes. The Company’s net deferred tax assets have been fully reserved by a tax valuation allowance.

The Company generated net income of $0.2 million for the three months ended September 30, 2015 compared to a net loss of ($0.1) million for the three months ended September 30, 2014.  Net income was positively impacted by improvement in operating income (discussed above).

The Company reported diluted income per share of $0.01 for the three months ended September 30, 2015 versus diluted loss per share of ($0.00) for the three months ended September 30, 2014.  Diluted income per share was positively impacted by improvement in net income (discussed above).
 
PROSPECTS FOR THE FUTURE

The Company continues to focus on core markets and solution offerings that fuel growth. Markets served are professional offices, retail pharmacies and clinics, assisted living and long-term care facilities, home healthcare, government, pharmaceutical manufacturers and other commercial organizations that require cost-effective services for managing medical, pharmaceutical and hazardous waste. 

The Company believes its growth opportunities are supported by the following:

·
A large professional market that consists of dentists, veterinarians, clinics, private practice physicians, urgent care facilities, ambulatory surgical centers and others such as acupuncture and tattoo services. This regulated market consists of small to medium quantity generators of medical, pharmaceutical and hazardous waste where we can offer a lower cost to service with solutions to match individual facility needs. The Company addresses this market from two directions: (i) field sales which focuses on larger-dollar and nationwide opportunities where we can integrate the route-based pickup service along with our mailback solutions to create a comprehensive medical waste management offering and (ii) inside and online sales which focus on the individual or small group professional offices.

·
The shift of healthcare from traditional settings to the retail pharmacy and clinic markets, where the Company focuses on driving increased promotion of the Sharps Recovery System. The number of U.S. retail clinics is projected to increase significantly, as much as 20%-25% per year, driven by the increasing demand of newly insured patients under healthcare reform, as well as patients looking for more convenient care and retail pharmacies increasing the variety and volume of healthcare services they provide. According to the Centers for Disease Control ("CDC"), 25% of flu shots for adults were administered in a retail clinic with the trend expected to increase. In addition to the continued growth in the flu shot business, there are also growth opportunities for more primary care in the retail or alternative site setting and correspondingly growth opportunities for the Company based on its significant presence in the retail market. A recent study shows that Americans visit retail clinics 10 million times a year, which represents only 2% of "all primary care patient encounters."

·
The passage of new regulations for ultimate user medication disposal allows the Company to offer new solutions (MedSafe and TakeAway Medication Recovery System envelopes) that meet the regulations for ultimate user controlled substances disposal (Schedules II-V) to retail pharmacies. Additionally, with the new regulations, the Company is able to provide the MedSafe and TakeAway Medication Recovery Systems to assisted living and hospice to address a long standing issue within long-term care.

·
The changing demographics of the U.S. population - one out of five Americans will be 65 years or older by 2030, which will increase the need for cost-effective medical waste management solutions, especially in the long-term care and home healthcare markets. With multiple solutions for managing regulated healthcare-related waste, the Company delivers value as a single-source provider with blended mailback and route-based pickup services matched to on the waste volumes of each facility.

·
Local, state and federal agencies have growing needs for solutions to manage medical and pharmaceutical waste — the Company's Sharps Recovery System is ideal for as-needed disposal of sharps and other small quantities of medical waste generated within government buildings, schools and communities. The Company also provides TakeAway Medication Recovery System envelopes and MedSafe solutions to government agencies in need of proper and regulatory compliant medication disposal.

·
With an increased number of self-injectable medication treatments and local regulations, the Company believes its flagship product, the Sharps Recovery System, continues to offer the best option for proper sharps disposal at an affordable price. The Company delivers premium services to pharmaceutical manufacturers that sell high-dollar, self-injectable medications, which include data management, compliance reporting, fulfillment, proper containment with disposal, branding and conformity with applicable regulations. In addition, the Company provides self-injectors with online and retail purchase options of sharps mailback systems, such as the Sharp Recovery System and Complete Needle Collection & Disposal System, respectively.

·
A heightened interest by many commercial companies who are looking to improve workplace safety with proper sharps disposal and unused medication disposal solutions — the Company offers a variety of services to meet these needs, including the Sharps Secure Needle Disposal System, Sharps Recovery System, Biohazard Spill Kits and TakeAway Medication Recovery System envelopes.

·
In July 2015, the Company augmented its network of medical and hazardous waste service providers with an acquisition of a route-based pickup service in the northeast serving Pennsylvania, Maryland and parts of Ohio. Additionally, the Company has begun to service parts of Texas and Louisiana with route-based pickup service. With the addition of these route-based pickup regions and the network of medical and hazardous waste service providers servicing the entire U.S., the Company offers customers a blended product portfolio to effectively manage multi-site and multi-sized locations, including those that generate larger quantities of waste. The network has had a significant positive impact on our pipeline of sales opportunities — over 60% of this pipeline is attributable to opportunities providing comprehensive waste management service offerings where both the mailback and pickup service are integrated into the offering.
 
·       The Company has new solution offerings that include ultimate user medication disposal (MedSafe and TakeAway Medication Recovery System) and mailback services for DEA registrant expired inventory of controlled substances (TakeAway Medication Recovery System DEA Reverse Distribution for Registrants).

·       The Company's strong financial position with a cash balance of $16.0 million and no debt as of September 30, 2015.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flow

Cash and cash equivalents increased by $0.8 million to $16.0 million at September 30, 2015 from $15.2 million at June 30, 2015. The increase in cash and cash equivalents is primarily due to a decrease in accounts receivable of $1.8 million, proceeds from the exercise of stock options of $0.3 million, and a decrease in prepaid and other current assets of $0.2 million.  The increase was offset in part by an increase in inventory of $0.7 million, payments for acquisition of $0.6 million and purchases of property, plant and equipment of $0.5 million in the three months ended September 30, 2015.

Accounts receivable decreased by $1.8 million to $4.9 million at September 30, 2015 from $6.6 million at June 30, 2015. The decrease is due to timing of billings and collections.

Inventory increased by $0.7 million to $3.4 million at September 30, 2015 from $2.7 million at June 30, 2015. The decrease in inventory is due to timing of sales and adjustment of inventory levels to facilitate customer orders.

Accounts payable and accrued liabilities decreased by $0.2 million to $3.5 million at September 30, 2015 from $3.7 million at June 30, 2015.  The increase is the result of the timing of payments.

Working capital decreased to $0.3 million to $19.4 million at September 30, 2015 from $19.7 million at June 30, 2015. The decrease is primarily due to the increase in inventory, payments for acquisition and purchases of property, plant and equipment offset by a decrease in accounts receivable, proceeds from the exercise of stock options and net income (discussed above).

Property, plant and equipment, increased $0.4 million to $4.2 million at September 30, 2015 from $3.8 million at June 30, 2015.  The increase is mainly attributable to capital expenditures of $0.5 million and acquired property, plant and equipment in connection with the acquisition of $0.1 million offset in part by depreciation expense of $0.2 million. Capital expenditures are attributable primarily to treatment facility improvements of $0.1 million and investment in MedSafe assets of $0.2 million.

Stockholders’ equity increased by $0.6 million to $24.2 million at September 30, 2015 from $23.6 million at June 30, 2015.  This increase is primarily attributable to the net income for the three months ended September 30, 2015 of $0.2 million, proceeds from the exercise of stock options of $0.3 million and stock-based compensation expense of $0.1 million.

Off-Balance Sheet Arrangements

The Company was not a party to any off-balance sheet transactions as defined in Item 303 of Regulation S-K for the three months ended September 30, 2015 and the year-ended June 30, 2015.

Credit Facility

On April 9, 2015, the Company entered into a credit agreement with a commercial bank (“Credit Agreement”). The Credit Agreement, which replaces, in its entirety, the Company’s prior credit agreement, which was executed effective January 28, 2014 with the same commercial bank, provides for a two-year, $9.0 million line of credit facility, the proceeds of which may be utilized as follows: (i) $4.0 million for working capital, letters of credit (up to $500,000) and general corporate purposes and (ii) $5.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by the Company’s accounts receivable and inventory with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus 50% of eligible inventory. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note. Borrowings bear interest at WSJ Prime (for the working capital line) and WSJ Prime plus 0.25% (for the acquisition line), which was approximately 3.25% and 3.50%, respectively, as of September 30, 2015. The Company pays a fee of 0.25% per annum on the unused amount of the line of credit. As of September 30, 2015, the Company had no outstanding borrowings other than $0.3 million in letters of credit, which left $8.7 million of credit available under the Credit Agreement.
 
The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $12.5 million, minimum liquidity of $7.0 million and a minimum debt service coverage ratio of not less than 1.15 to 1.00. The Credit Agreement, which expires on April 9, 2017, also contains customary events of default which, if uncured, may terminate the Credit Agreement and require immediate repayment of all indebtedness to the lenders. The Company was in compliance with all the financial covenants under the Credit Agreement as of September 30, 2015.

Management believes that the Company’s current cash resources (cash on hand) will be sufficient to fund operations for the twelve months ending September 30, 2016.

CRITICAL ACCOUNTING ESTIMATES

Revenue Recognition The Company recognizes revenue from product sales and services when goods are shipped or delivered, services provided, and title and risk of loss pass to the customer except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.  Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse.

Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ and various other solutions like the TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service.

In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.  The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.  The selling price for the transportation revenue and the treatment revenue utilizes third party evidence.  The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.  Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities.  The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities.  Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.  Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.  The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.  Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned.  Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.

Income Taxes :  Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets.  Under generally accepted accounting principles, the valuation allowance has been recorded to reduce our deferred tax assets to an amount that is more likely than not to be realized and is based on the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.

Stock-Based Compensation : Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).
 
RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, guidance for revenue recognition was issued which supersedes the revenue recognition requirements currently followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. In July 2015, the FASB decided to defer the original effective date by one year to be effective for annual reporting periods beginning after December 15, 2017 instead of December 15, 2016 for public entities (effective July 1, 2018 for the Company).  The Company is still evaluating the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures and has not yet determined the method by which it will adopt the standard.

In July 2015, guidance for inventory measurement was issued, which supersedes the policy currently followed by the Company.  The new guidance requires the Company to measure inventory at the lower of cost or net realizable value.  The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2016 (effective July 1, 2017 for the Company) including interim periods within the reporting period.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In September 2015, guidance for business combinations was issued, which simplifies the accounting for measurement-period adjustments.  The new guidance eliminates the requirement to restate prior period financial statements for measurement period adjustments following a business combination and requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified.  The provisions of the new guidance are effective for annual reporting periods beginning after December 15, 2015 (effective July 1, 2016 for the Company) including interim periods within the reporting period.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company does not have exposure to significant financial market risk including commodity price risk, foreign currency exchange risk or interest rate risk. Management does not use derivative instruments. The Company has limited exposure to changes in interest rates due to its lack of indebtedness.  The Company maintains a credit agreement under which we may borrow funds in the future. The Company does not currently foresee any borrowing needs.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures”, as such term is defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including, the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) as appropriate, to allow timely decisions regarding required disclosure.

The Company conducted an evaluation (the “Evaluation”), under the supervision and with the participation of the CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”) as of September 30, 2015, pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act.  Based upon this Evaluation, the CEO and CFO concluded that our Disclosure Controls were effective as of September 30, 2015.

Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2015, there were no changes in the Company’s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act), that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

CEO and CFO Certifications

Appearing immediately following the Signatures section of this report are certifications of the CEO and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This item of this Quarterly Report on Form 10-Q, which you are currently reading, is the information concerning the Evaluation referred to in the Section 302 Certification and this information should be read in conjunction  with the Section 302 Certifications for a more complete understanding of the topics presented.
 
PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is involved in legal proceedings and litigation in the ordinary course of business.  In the opinion of management, the outcome of such matters will not have a material adverse effect on the Company’s consolidated financial position or consolidated results of operations.

ITEM 1A. RISK FACTORS

Refer to Item 1A. Risk Factors in the Company’s annual report on Form 10-K for the year ended June 30, 2015 for the Company’s risk factors.  During the three months ended September 30, 2015, there have been no changes to the Company’s risk factors.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Recent Sales of Unregistered Securities.

None.

Issuer Purchases of Equity Securities.

On January 7, 2013, the Company announced that its Board of Directors approved a stock repurchase program effective January 3, 2013, authorizing the Company to repurchase in the aggregate up to $3.0 million of its outstanding common stock over a two-year period.  On March 5, 2015, the Board approved a two-year extension of the stock repurchase program through January 1, 2017. The shares would be purchased from time to time on the open market or in privately negotiated transactions, at the Company's discretion, in each case, in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, subject to market and business conditions, applicable legal requirements, explicit black-out dates and other factors. The purchases will be funded using the Company's available cash balances and cash generated from operations. The program does not obligate the Company to acquire any particular amount of common stock and may be modified, suspended or terminated at any time at the Company's discretion in accordance with Rule 10b-18.

During the three months ended September 30, 2015, Sharps repurchased no shares.  As of September 30, 2015, approximately $2.2 million remained of our $3.0 million repurchase program.

ITEM 6.
EXHIBITS

(a)
Exhibits:
   
Certification of Chief Executive Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
   
Certification of Chief Financial Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
   
Certification of Chief Executive Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)
   
Certification of Chief Financial Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)
   
101.INS
XBRL Instance Document (filed herewith)
   
101.SCH
XBRL Taxonomy Extension Schema Document (filed herewith)
   
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)
   
101.DEF
XBRL Taxonomy Extension Linkbase Document (filed herewith)
   
101.LAB
XBRL Taxonomy Extension Label Linkbase Document (filed herewith)
   
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)

ITEMS 3, 4 AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
REGISTRANT:
 
SHARPS COMPLIANCE CORP.
   
Dated: November 4, 2015
By: /s/ DAVID P. TUSA   
 
David P. Tusa
 
Chief Executive Officer and President
 
(Principal Executive Officer)

Dated: November 4, 2015
By: /s/ DIANA P. DIAZ   
 
Diana P. Diaz
 
Vice President and Chief Financial Officer
 
(Principal Financial and Accounting Officer)
 
 
20

 

Exhibit 31.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, David P. Tusa, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: November 4, 2015
/s/David P. Tusa
 
Chief Executive Officer and President
 
(Principal Executive Officer)
 
 


Exhibit 31.2
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER
IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, Diana P. Diaz, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: November 4, 2015
/s/Diana P. Diaz
 
Vice President and Chief Financial Officer
 
(Principal Financial and Accounting Officer)
 
 


Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the three months ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof, I, David P. Tusa, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1) The Form 10-Q report for the three months September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Form 10-Q report for the three months ended September 30, 2015 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.

Date: November 4, 2015
/s/David P. Tusa
 
Chief Executive Officer and President
 
 


Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the three months ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof, I, Diana P. Diaz, Vice President and Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1) The Form 10-Q report for the three months ended September 30, 2015, filed with the Securities and Exchange Commission on November 6, 2015 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Form 10-Q report for the three months ended September 30, 2015 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.

Date: November 4, 2015
/s/Diana P. Diaz
 
Vice President and Chief Financial Officer